# Tirzepatide Weight Loss: The Trial Evidence > Tirzepatide weight loss outcomes from the SURMOUNT Phase 3 programme, SURMOUNT-5 head-to-head 2025, and the 2025 diabetes-prevention follow-up — every figure cited to the source. Tirzepatide documented. ## The short version Tirzepatide weight loss outcomes are the most impressive recorded in a randomised obesity drug trial. In SURMOUNT-1, the largest Phase 3 trial, participants without type 2 diabetes lost an average of 15.0% of body weight at the lowest studied maintenance dose (5 mg) and 20.9% at the highest (15 mg) over 72 weeks — compared with 3.1% in the placebo group. A 2025 head-to-head trial against semaglutide (a selective GLP-1 receptor agonist) found tirzepatide produced -20.2% mean weight change versus -13.7% with the comparator. A separate 2025 follow-up also found sustained tirzepatide weight loss reduced progression to type 2 diabetes in people with obesity. The mechanism involves dual GIP/GLP-1 receptor activation reducing appetite, slowing gastric emptying, and enhancing insulin signalling — the result is a caloric deficit that most participants sustain over the full trial duration. ## Tirzepatide weight loss: what SURMOUNT-1 measured SURMOUNT-1 (Jastreboff AM, et al.; NEJM 2022; NCT04184622) enrolled 2,539 adults with obesity (BMI ≥30, or ≥27 with a weight-related complication — such as hypertension, dyslipidaemia, or obstructive sleep apnea) and without type 2 diabetes. Participants received once-weekly subcutaneous tirzepatide (5, 10, or 15 mg) or placebo for 72 weeks; the 20-week dose-escalation phase preceded maintenance at the assigned dose. Mean percentage body-weight change at week 72 [4]: - 5 mg: -15.0% - 10 mg: -19.5% - 15 mg: -20.9% - Placebo: -3.1% All three tirzepatide doses were significantly superior to placebo (P<0.001). Proportions reaching ≥5%, ≥10%, ≥15%, and ≥20% weight loss were significantly higher for all tirzepatide groups. The most common adverse events were gastrointestinal (predominantly nausea), most frequent during dose escalation, and mostly mild to moderate. The weight-loss magnitude — approximately 21% mean loss at the maximum dose — was the largest ever reported in a randomised controlled obesity pharmacotherapy trial at the time of publication. ## Tirzepatide weight loss: the 2025 head-to-head comparison (SURMOUNT-5) SURMOUNT-5 (Aronne LJ, et al.; NEJM 2025; NCT05822752) was a phase 3b, open-label, randomised controlled trial in 751 adults with obesity (BMI ≥30, or ≥27 with a complication) but without type 2 diabetes. Participants received the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (a selective GLP-1 receptor agonist — 1.7 or 2.4 mg), once weekly for 72 weeks [5]. This is the only large randomised head-to-head weight-management comparison of the two drugs. Least-squares mean weight change at week 72: - Tirzepatide: -20.2% - Semaglutide: -13.7% - Difference: -6.5 percentage points (P<0.001) Tirzepatide also produced greater reductions in waist circumference and higher proportions of participants reaching each weight-loss threshold (10%, 15%, 20%, and 25%). The adverse event profile was consistent with the established safety record: gastrointestinal events were the most common in both groups. The SURMOUNT-5 result provides the first head-to-head randomised evidence for tirzepatide's superiority over semaglutide in [tirzepatide weight loss](/weight-loss) specifically in adults with obesity without diabetes. ## Tirzepatide weight loss and diabetes prevention — 2025 follow-up Jastreboff AM, et al. (NEJM 2025) reported the outcomes of a follow-up study examining whether tirzepatide-induced weight reduction reduced progression to type 2 diabetes in adults with obesity. The study found sustained weight reduction and reduced progression to type 2 diabetes in the tirzepatide group [36]. This extends the significance of tirzepatide weight loss beyond aesthetics or mobility to diabetes primary prevention — particularly relevant given that the drug is already approved for type 2 diabetes treatment. Tirzepatide weight loss and concomitant weight-inducing medications: A 2026 post-hoc analysis of SURMOUNT-1, -3, and -4 (Galindo et al.) found that approximately 17–20% of participants across the trials were also taking medications that promote weight gain. Their percentage weight changes with tirzepatide (-13.3% at 5 mg to -21.3% at 15 mg in SURMOUNT-1; -26.1% at maximum tolerated dose in SURMOUNT-3; -18.6% at maximum tolerated dose in SURMOUNT-4) were comparable to the primary results not stratified by weight-inducing medication use [37]. This suggests the drug's efficacy is broadly maintained even when participants are also taking treatments that work against weight loss. ## How does tirzepatide work for weight loss? Tirzepatide achieves its weight-loss effect through dual incretin receptor activation — engaging both the GIP receptor and the GLP-1 receptor simultaneously. The downstream effects relevant to body-weight reduction are: 1. **Reduced appetite and food intake** — GLP-1R activation in the hypothalamus and brainstem suppresses hunger signals; GIP receptor activation in fat and potentially in the brain also contributes to reduced energy intake. 2. **Delayed gastric emptying** — food leaves the stomach more slowly, extending satiety and blunting post-meal glucose spikes. 3. **Enhanced glucose-dependent insulin secretion** — dual receptor activation produces more insulin in response to elevated blood glucose, improving metabolic efficiency. 4. **Glucagon suppression** — reduced pancreatic glucagon (the hormone that raises blood sugar) lowers hepatic glucose output. The additive effect of GIP receptor activation on top of GLP-1 receptor activation appears to be the key to the larger weight losses observed versus selective GLP-1 receptor agonists, as the preclinical data (Coskun et al., 2018) and the head-to-head SURMOUNT-5 results both confirm [1, 5]. Whether dual agonism produces strictly additive or synergistic effects, and the precise contribution of each receptor to the weight outcome, remain active areas of investigation. --- A newsroom reading of the tirzepatide safety record — the 2024–2025 trials and meta-analyses set down and cited, with no clinic, no prescriber, and no verdict on any individual's risk.